MCE products for research use only. We do not sell to patients.

RCM-1

MCE China：RCM-1

Brand：MedChemExpress (MCE)

Cat. No.HY-19979

CAS：339163-65-4

Purity：98.56%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.

In Vitro：RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1, a transcription factor critical for the differentiation of goblet cells from airway progenitor cells. In cultured airway epithelial cells, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3, which are key transcriptional regulators of goblet cell differentiation[1].

In Vivo：RCM-1 reduces airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia. In mice, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3[1].

Animal Administration：Mice[1] Mouse Rd76-9 rhabdomyosarcoma cells (1×106 cells) are injected intramuscularly in the flanks of C56Bl/6J mice (n=8 mice per group). Seven days after the tumor cells inoculation, 40 μL of either Vehicle (DMSO) or RCM-1 (20 mg/kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 16. RCM-1 treatment decreases Rd76-9 tumor growth as compared to the DMSO-treated group. Mouse B 16-FlO melanoma cells (1×106 cells) are injected subcutaneously in C56Bl/6J mice (n=7 animals per group). Three days after the tumor cell inoculation, 40 μL of either Vehicle (DMSO) or RCM1 (20 mg/Kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 12[1].

Cell Assay：Rd76-9 rhabdomyosarcoma, B16-FlO melanoma, H2122 lung adenocarcinoma, 4T1 breast carcinoma, MyC-CaP prostate carcinoma and KPC-2 pancreatic carcinoma cells are seeded in 6-well plates and incubated overnight. The cells are treated with 20 μM concentration of RCM-1 for 24, 48 and 72 h and cell growth is analyzed by counting alive cells using trypan blue. Cells treated with DMSO are used as controls[1].

IC50 & Target：FOXM1[1]. In Vitro RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1, a transcription factor critical for the differentiation of goblet cells from airway progenitor cells. In cultured airway epithelial cells, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3, which are key transcriptional regulators of goblet cell differentiation[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> RCM-1 Related Antibodies

Hot selling product：N-Nitrosodibutylamine  | Trastuzumab duocarmazine  | Sulindac  | EUK-134  | SRX3207  | Rabdosiin  | (S)-Pro-xylane  | Berbamine (dihydrochloride)  | Lactulose  | NS 11024

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Lifeng Sun, et al. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017 Apr 18;10(475):eaai8583.  [Content Brief]